William Read
- Department of Hematology and Medical Oncology
Associate Professor
- (404) 778-1900
- william.l.read@emory.edu
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- BA from Carleton College
- MD from University of Nebraska Medical Center, College of Medicine
Research
Focus
- I am a clinician and my time is spent in patient care and designing / conducting clinical trials. I am interested in novel methods of cancer treatment and also the repurposing of available drugs/treatments to serve new uses.
Publications
-
Genomic Insights Into High-Grade Infarct-Associated Bone Sarcomas.
Mod Pathol Volume: 37 Page(s): 100572
10/01/2024 Authors: Tvrdik T; Gjeorgjievski SG; Wong P; Oskouei S; Read W; Bahrami A -
Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity.
Case Rep Oncol Volume: 17 Page(s): 202 - 207
01/01/2024 Authors: Menon A; Enunwa CA; Read WL; James KP -
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
N Engl J Med Volume: 389 Page(s): 911 - 921
09/07/2023 Authors: Chen AP; Sharon E; O'Sullivan-Coyne G; Moore N; Foster JC; Hu JS; Van Tine BA; Conley AP; Read WL; Riedel RF -
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Front Endocrinol (Lausanne) Volume: 14 Page(s): 1195792
01/01/2023 Authors: Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S -
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
Eur J Cancer Volume: 176 Page(s): 155 - 163
11/01/2022 Authors: Rosenbaum E; Chugh R; Ryan CW; Agulnik M; Milhem MM; George S; Jones RL; Chmielowski B; Van Tine BA; Tawbi H -
Impact of Metastasectomy and Aggressive Local Therapy in Newly Diagnosed Metastatic Soft Tissue Sarcoma: An Analysis of the NCDB.
Ann Surg Oncol Volume: 29 Page(s): 649 - 659
01/01/2022 Authors: Abugideiri M; Janopaul-Naylor J; Switchenko J; Tian S; Read W; Press R; Oskouei S; Reimer N; Ferris M; Cassidy RJ -
ASO Visual Abstract: Impact of Metastasectomy and Aggressive Local Therapy in Newly Diagnosed Metastatic Soft Tissue Sarcoma: An Analysis of the NCDB.
Ann Surg Oncol Volume: 28 Page(s): 579 - 580
12/01/2021 Authors: Abugideiri M; Janopaul-Naylor J; Switchenko J; Tian S; Read W; Press R; Oskouei S; Reimer N; Ferris M; Cassidy RJ -
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Cancer Volume: 127 Page(s): 894 - 904
03/15/2021 Authors: Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY -
Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.
Sci Rep Volume: 10 Page(s): 14449
09/02/2020 Authors: Lorza AMA; Ravi H; Philip RC; Galons J-P; Trouard TP; Parra NA; Von Hoff DD; Read WL; Tibes R; Korn RL -
Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).
Volume: 37
05/20/2019 Authors: Somaiah N; Van Tine BA; Hill EG; Milhem MM; Schuetze S; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP